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642REPLY: Coronary In-Stent Restenosis in
Patients Treated With Thoracic External
Beam Radiation for CancerWe thank Drs. Montone, Minelli, and Niccoli for their
thoughtful letter in response to our paper (1). Our
institution is a tertiary referral center, and many pa-
tients treated with external beam radiation therapy
(EBRT) and percutaneous coronary intervention
(PCI) with stents at the Mayo Clinic received their
chemotherapy elsewhere. Because precise informa-
tion regarding chemotherapy duration and speciﬁc
regimen were unavailable for all patients, we chose
not to include data on chemotherapeutic agents in our
study. Although we acknowledged in our study limi-
tations that the use of cardiotoxic chemotherapy may
have been an unmeasured confounder with respect to
adverse impact on long-term outcomes (1), we did not
mention the potential of chemotherapeutic drugs to
positively inﬂuence long-term stent related outcomes.
Montone et al. raise a valid point that certain
antiproliferative agents (including paclitaxel and
ﬂudarabine) have been used for drug-eluting stent
technology to reduce neointimal proliferation. The
effects of systemic administration of these medica-
tions at high doses (such as those administered as
treatment for cancer) on neointimal proliferation and
stent restenosis or healing remain entirely unknown.
Systemic administration of anti-inﬂammatory and
antiproliferative medications, including prednisone,
sirolimus, and colchicine, has been shown to
decrease stent restenosis rates in patients with bare-
metal stents when given shortly following stent im-
plantation (2–5). It is important to note that in our
study, the median intervals between PCI and EBRT
(and likely chemotherapy) in both Group A and
Group B patients were 3.6 and 2.2 years, respectively,whereas in the aforementioned studies, the systemic
agents were administered immediately following
stent implantation. Regardless, it remains possible,
though unlikely, that antiproliferative chemothera-
peutic agents may have affected rates of stent reste-
nosis, particularly in patients treated with bare-metal
stents. Thus, the effects of systemically administered
chemotherapeutic agents on stent failure certainly
merits further study.Jackson J. Liang, DO
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